{"gao_id": "GAO-09-866", "published": "2009-09-23T13:09:00Z", "released": "2009-10-26T09:10:00Z", "summary": "", "title": "New Drug Approval: FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints", "topics": ["AIDS", "Standards", "Monitoring", "Anthrax", "Internal controls", "Substance abuse treatment", "Product safety", "Strategic planning", "Cancer", "Trials", "Diseases", "Medically necessary treatments", "Health Care", "Therapy", "Data collection", "Cancer research", "Requirements definition", "Drug approvals", "Reporting requirements"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-09-866", "versions": [{"title": "Highlights", "url": "https://www.gao.gov/assets/gao-09-866-highlights.pdf"}, {"title": "Full Report (71 pages)", "url": "https://www.gao.gov/assets/gao-09-866.pdf"}, {"title": "Accessible Text", "url": "https://www.gao.gov/assets/a295766.html"}]}